AUSTIN,
Texas, July 2, 2024 /PRNewswire/ -- Alafair
Biosciences, Inc., is revolutionizing soft tissue protection with
innovative hydrogel medical devices, today announced that its
flagship product, VersaWrap Hydrogel Sheet (VersaWrap), has been
awarded a national group purchasing agreement with Premier, Inc.
Effective July 1, 2024, the new
agreement allows Premier members, at their discretion, to take
advantage of special pricing and terms pre-negotiated by Premier
for VersaWrap. VersaWrap is a class II medical device that allows
tissues to glide and to remain untethered, thereby reducing
reoperations and improving patient outcomes.
![VersaWrap is an FDA-cleared medical device implant (not tissue) comprising hyaluronic acid (HA) and alginate that provides a gelatinous encasement for peripheral nerves, tendons, and surrounding tissues such as ligaments and skeletal muscles. Our innovative technology allows tissues to glide and to remain untethered, thereby reducing reoperations and improving patient outcomes. VersaWrap is an FDA-cleared medical device implant (not tissue) comprising hyaluronic acid (HA) and alginate that provides a gelatinous encasement for peripheral nerves, tendons, and surrounding tissues such as ligaments and skeletal muscles. Our innovative technology allows tissues to glide and to remain untethered, thereby reducing reoperations and improving patient outcomes.](https://mma.prnewswire.com/media/2452573/696_VersaWrap_logo_with_slogan_sheet_and_gel.jpg)
"We are honored that Premier and its members reviewed our
technology and awarded Alafair an agreement," stated John Joyoprayitno, President & CEO of
Alafair Biosciences. "This agreement provides a meaningful
opportunity for Alafair to broaden VersaWrap's reach to Premier
members, clinicians, and, most importantly, patients nationwide. We
anticipate this agreement to further fuel our momentum and enable
us to continue delivering over 100% year-over-year growth."
Premier is a leading healthcare improvement company, uniting an
alliance of approximately 4,350 U.S. hospitals and 300,000 other
providers to transform healthcare. With integrated data and
analytics, collaboratives, supply chain solutions, consulting, and
other services, Premier enables better care and outcomes at a lower
cost.
About Alafair Biosciences, Inc.
Alafair is a privately held medical device company developing
and marketing an innovative product portfolio based on its
proprietary hydrogel technology. The mission of Alafair is to
revolutionize surgical care with our versatile hydrogel technology,
delivering unparalleled value to patients, surgeons, and healthcare
facilities by enhancing soft tissue protection and by elevating
patient outcomes. Alafair products are distributed through a
dispersed network of independent distributors across the
United States.
About VersaWrap® Hydrogel Sheet
VersaWrap is an FDA-cleared medical device implant (not tissue)
comprising hyaluronic acid (HA) and alginate that provides a
gelatinous encasement for peripheral nerves, tendons, and
surrounding tissues such as ligaments and skeletal muscles. Our
innovative technology allows tissues to glide and to remain
untethered, thereby reducing reoperations and improving patient
outcomes. VersaWrap offers unique surgical flexibility as the only
tendon and nerve protector that can be delivered either as a sheet
or as a flowable gel.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alafair-biosciences-awarded-synthetic-implantable-products-agreement-with-premier-inc-for-versawrap-hydrogel-sheet-302188127.html
SOURCE Alafair Biosciences, Inc.